Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $38.6 million.

  • Benitec Biopharma's Shares Outstanding (Weighted Average) rose 11113.48% to $38.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $38.6 million, marking a year-over-year increase of 11113.48%. This contributed to the annual value of $18.4 million for FY2024, which is 122516.58% up from last year.
  • Per Benitec Biopharma's latest filing, its Shares Outstanding (Weighted Average) stood at $38.6 million for Q1 2025, which was up 11113.48% from $37.3 million recorded in Q4 2024.
  • Benitec Biopharma's 5-year Shares Outstanding (Weighted Average) high stood at $38.6 million for Q1 2025, and its period low was $480688.0 during Q2 2022.
  • In the last 5 years, Benitec Biopharma's Shares Outstanding (Weighted Average) had a median value of $4.7 million in 2021 and averaged $10.8 million.
  • As far as peak fluctuations go, Benitec Biopharma's Shares Outstanding (Weighted Average) plummeted by 9218.56% in 2022, and later skyrocketed by 134603.34% in 2024.
  • Over the past 5 years, Benitec Biopharma's Shares Outstanding (Weighted Average) (Quarter) stood at $8.2 million in 2021, then plummeted by 80.16% to $1.6 million in 2022, then skyrocketed by 58.91% to $2.6 million in 2023, then surged by 1346.03% to $37.3 million in 2024, then increased by 3.61% to $38.6 million in 2025.
  • Its last three reported values are $38.6 million in Q1 2025, $37.3 million for Q4 2024, and $27.9 million during Q3 2024.